Celltrion and Rani Therapeutics (Rani) have entered a partnership under which Celltrion will supply ustekinumab and adalimumab biosimilars for RaniPill products under an exclusive license and supply agreement.
In January 2023, it was announced that Celltrion will supply Rani’s ustekinumab biosimilar drug substance, CT-P43, for the oral RT-111 RaniPill programme. Now, in June 2023, a second deal is made that Celltrion will exclusively supply Rani with the adalimumab biosimilar drug substance (CT-P17) required for its RT-105 RaniPill.
In 2021 and 2022, Rani announced the launch and development of new oral, needle-free methods to deliver large biological drug molecules, such as ustekinumab [1] and adalimumab [2]. These are known as RaniPills RT-111 and RT-105, respectively. The RaniPill capsule is designed to administer biologicals with bioavailability comparable to subcutaneous injection.
The recent partnership will see the development and supply of the biosimilars for these pills. Under the terms of the agreement, Celltrion will exclusively supply to Rani the ustekinumab (CT-P43) and adalimumab (CT-P17) biosimilar drug substances required for the RaniPills. Rani is granted an exclusive license to use CT-P43 and CT-P17 in the development and commercialization of RT-111 and RT-105, and Celltrion is granted a right of first negotiation to acquire worldwide rights to RT-111 and RT-105 following a phase I clinical trial.
|
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View the latest headline article: Actualización de la declaración de posición de GADECCU sobre los biosimilares Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Ver el último artículo de cabecera: Actualización de la declaración de posición de GADECCU sobre los biosimilares !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
Related articles
New adalimumab biosimilars prepare to launch in Canada, US and Europe
Amgen announces positive phase III results for ustekinumab biosimilar
References
1. GaBI Online - Generics and Biosimilars Initiative. Ustekinumab biosimilars: new international biopharma agreements [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jul 14]. Available from: www.gabionline.net/pharma-news/ustekinumab-biosimilars-new-international-biopharma-agreements
2. GaBI Online - Generics and Biosimilars Initiative. Needle-free delivery of biological drugs from Rani and Progenity (gabionline.net) [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Jul 14]. Available from: www.gabionline.net/biosimilars/general/needle-free-delivery-of-biological-drugs-from-rani-and-progenity
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment